Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

759
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
759
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

533
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
533
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

510
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
510
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

489
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
489
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

468
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
468

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effect of Behavioral Sleep Interventions on Measures of Obesity, Dietary Intake and Physical Activity in Adults With Poor Sleep Health: A Systematic Review, Meta-Analysis and Meta-Regression Analysis.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2026
Same author

Hyperinsulinaemia as a cause of obesity and cardiometabolic diseases.

Nature reviews. Endocrinology·2026
Same author

Effect of behavioural sleep interventions on blood pressure, heart rate, and heart rate variability in adults with poor sleep health: a systematic review, meta-analysis, and meta-regression analysis.

European heart journal open·2026
Same author

Correction to: Safety of Bariatric Surgery in ≥ 65-Year-Old Patients during the COVID-19 Pandemic.

Obesity surgery·2026
Same author

Change in body mass index and disease burden among people with obesity and multiple long-term conditions.

Diabetes, obesity & metabolism·2026
Same author

The Identification of Potential Treatment Targets to Reduce the Risk of Obesity-Related Complications: A Step Toward a Treat-to-Target Approach in Obesity Management.

Obesity science & practice·2025

Related Experiment Video

Updated: Dec 26, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.0K

Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments.

Konstantinos A Toulis1,2, Krishnarajah Nirantharakumar1, Chrysa Pourzitaki3

  • 1Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

Drugs
|March 13, 2020
PubMed
Summary

Glucokinase activators (GKAs) offer a novel approach to manage Type 2 diabetes mellitus (T2DM) by targeting increased hepatic glucose output. These activators may improve glycemic control by enhancing insulin secretion and liver glucose uptake.

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

95.5K
Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets
09:31

Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets

Published on: June 25, 2012

14.3K

Related Experiment Videos

Last Updated: Dec 26, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.0K
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

95.5K
Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets
09:31

Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets

Published on: June 25, 2012

14.3K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) is characterized by increased hepatic glucose output, a key dysregulation not effectively managed by current therapies besides metformin.
  • Glucokinase (GK) plays a crucial role as a glucose sensor in pancreatic beta cells and a glucose gatekeeper in hepatocytes.

Purpose of the Study:

  • To explore glucokinase activators (GKAs) as a therapeutic strategy for T2DM.
  • To review the role, efficacy, safety, and future prospects of GKAs in T2DM management.

Main Methods:

  • Review of existing literature on glucokinase activators and their mechanisms of action.
  • Discussion of novel GKAs like dorzagliatin and TTP399.

Main Results:

  • GK activation enhances glucose-stimulated insulin secretion and promotes hepatic glucose uptake and glycogen synthesis.
  • GKAs have the potential to reduce hepatic glucose output and improve glycemic control in T2DM patients.

Conclusions:

  • GKAs represent a promising therapeutic avenue for T2DM, addressing unmet needs in glycemic control.
  • Despite past challenges, renewed interest in GKAs, including novel agents, warrants further investigation for T2DM management.